Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 3/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 2/20 | 0.33 |
| ▸ | SNCA | P37840 | 1/20 | 0.33 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.31 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KRAS | P01116 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13768045 | 0.84 | NFE2L2 (0.50) | PTGS1PTGS2ALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL13730037 | 0.83 | HSD11B1 (0.56) | EGFRHSD11B1TNFRSF1ASLC5A1SLC5A2 | |
| SCHEMBL13730038 | 0.83 | HSD11B1 (0.56) | EGFRHSD11B1TNFRSF1ASLC5A1SLC5A2 | |
| SCHEMBL13489637 | 0.79 | CYP1A1 (0.48) | BACE1PTGS2HSD11B1HDAC1HDAC3 | |
| SCHEMBL31308838 | 0.79 | CYP1A1 (0.48) | BACE1PTGS2HSD11B1HDAC1HDAC3 | |
| SCHEMBL13948725 | 0.76 | BACE1 (0.49) | BACE1PTGS1PTGS2HDAC1HDAC6 | |
| SCHEMBL29910010 | 0.75 | MAPT (0.53) | EGFRHDAC1HDAC3HDAC6TNFRSF1A | |
| SCHEMBL13948724 | 0.75 | MAPT (0.53) | EGFRHDAC1HDAC3HDAC6TNFRSF1A | |
| SCHEMBL13460135 | 0.72 | ESR1 (0.46) | SLC5A1SLC5A2ALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL14416201 | 0.72 | MAPT (0.51) | SLC5A1SLC5A2ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113923988-B | Substituted arylmethyl ureas and heteroarylmethyl ureas, analogs thereof, and methods of using the same | 爱彼特生物制药公司 | 2024-12-13 | — | — | CN | disclosed |
| EP-3893645-B1 | SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2024-04-17 | — | — | EP | disclosed |
| US-20230045421-A1 | SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2023-02-09 | — | — | US | disclosed |
| US-20230045421-A1 | SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2023-02-09 | — | — | US | disclosed |
| CN-113923988-A | Substituted arylmethyl and heteroarylmethyl ureas, analogs thereof, and methods of using the same | 爱彼特生物制药公司 | 2022-01-11 | — | — | CN | disclosed |
| EP-3893645-A1 | SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2021-10-20 | — | — | EP | disclosed |
| WO-2020123674-A1 | SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230045421-A1 | SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME | HAVCR2, HMBS, AHCY | BACE1 3479/4885PTGS1 4356/4885PTGS2 4325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.